Ann: H1 2023 Preclinical and Clinical Programs Update, page-73

@Wasabi193 I think the answer ought to be outlined in the strategic update. Partnership is becoming more likely, feels we are going to take this thing into P3 rather than sell of the back of P2. Keeps the newcomers in a job but ‘risk on’ for longer.

if correct this takes cash, cash, more cash, and, expertise. Pharma also like there hand in things for any pivotal trials. Down to timing I foresee, P2 data for cardio protect in peer review / publication as a catalyst. A US IND would need opening and I would like to see breakthrough therapy designation and enter US P3.

By then we need the money so cap raise or partner, need to plant the seed now and nurture so when P2 data is ready Pharma are good to ink the term sheet. Failing that a US raise would make sense and a quick foot in the door to capital, don’t see another raise in Aus than isnt sub par.

time will tell we are in Q3 so not long to wait for the strategic update.